Veracyte (VCYT)
(Delayed Data from NSDQ)
$19.48 USD
-0.42 (-2.11%)
Updated Apr 25, 2024 03:59 PM ET
After-Market: $19.48 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Income Statements
Fiscal Year end for Veracyte, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 361 | 297 | 220 | 117 | 120 |
Cost Of Goods | 113 | 102 | 74 | 41 | 37 |
Gross Profit | 248 | 195 | 145 | 76 | 84 |
Selling & Adminstrative & Depr. & Amort Expenses | 334 | 236 | 227 | 111 | 99 |
Income After Depreciation & Amortization | -86 | -41 | -82 | -35 | -15 |
Non-Operating Income | 9 | 5 | 0 | 1 | 3 |
Interest Expense | 0 | 0 | 0 | 0 | 1 |
Pretax Income | -77 | -36 | -82 | -35 | -13 |
Income Taxes | -2 | 0 | -6 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -74 | -37 | -76 | -35 | -13 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -74 | -37 | -76 | -35 | -13 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -59 | -15 | -62 | -27 | -11 |
Depreciation & Amortization (Cash Flow) | 27 | 26 | 20 | 8 | 4 |
Income After Depreciation & Amortization | -86 | -41 | -82 | -35 | -15 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 72.65 | 71.55 | 67.89 | 53.24 | 46.14 |
Diluted EPS Before Non-Recurring Items | -0.28 | -0.51 | -0.49 | -0.66 | -0.27 |
Diluted Net EPS (GAAP) | -1.02 | -0.51 | -1.11 | -0.66 | -0.27 |
Fiscal Year end for Veracyte, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 98.20 | 90.11 | 90.32 | 82.42 |
Cost Of Goods | NA | 29.38 | 27.61 | 29.69 | 26.23 |
Gross Profit | NA | 68.82 | 62.50 | 60.63 | 56.19 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 104.32 | 94.24 | 68.68 | 66.69 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -35.50 | -31.74 | -8.05 | -10.50 |
Non-Operating Income | NA | 5.03 | 1.97 | -0.23 | 2.41 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -30.47 | -29.77 | -8.28 | -8.09 |
Income Taxes | NA | -2.18 | -0.15 | 0.13 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -28.29 | -29.62 | -8.40 | -8.09 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -28.29 | -29.62 | -8.40 | -8.09 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 73.11 | 72.81 | 72.48 | 72.18 |
Diluted EPS Before Non-Recurring Items | NA | -0.04 | -0.03 | -0.12 | -0.11 |
Diluted Net EPS (GAAP) | NA | -0.38 | -0.41 | -0.12 | -0.11 |